

. 62-66.
9. . . , . . . , . . .
.
99 - .
, 1997. - 6. - . 10-14.

10. Amendola M. A., Glaser C. M., et al. Myositis ossificans circumscripta: Computed tomographic diagnosis // *Radiology*. - 1993. - Bd. 140, H. 3. - S. 775 - 779.

11. Lin W.Y., Kao C.H., Wang S.J. Subcutaneous hematoma detected on Tc - 99m pyrophosphate muscle imaging // *Clin Nucl Med*. - 1998 Jan. - N. 23(1). - P. 56.

12. McAfee P.C., Cunningham B.W., Devine J., Williams E, Yu-Yahiro J. Classification of heterotopic ossification (HO) in artificial disk replacement // *J. Spinal. Disord. Tech.* - 2003. - Vol. 16, 4. - P. 384-389.

13. Pelissier J. et al. Treatment of neurogenic heterotopic ossifications (NHO) in brain injured patients: review of literature // *Ann. Readapt. Med. Phys.* - 2002. - Vol. 45, 5. - P. 188-197.

14. Reinartz P., Schaffeldt I., Sabri O. et al. (. .) // . - 2001. - 1. - . 69-63.

618.14-072.1

. . . , . . . , . . . ,
3 « »
. . . , . . . , -
, « » 3
. 119
. . . ,
(,),
, ,
:
, .

[2, 4, 8, 11].

[4].

60%

[2, 5, 18]. 22

[1, 5, 11].

– 12 I 15
II

119

25 45

« ».

I


38,0±2,3 20 45 (.1).

I

(%)


	20 25	25 30	30 35	35 40	40 45
(=119):	1	13	15	2	54
	0,8±0,5	10,5±1,9	12,6±2,1	29,2±2,9	46,9±3,2

40 45 35 40



. 1.

46,4% (56), 30,2% (36), 19,8% (22), 4,1% (5), 1,1% (1) (. 2).



. 2.

... : 13,1±0,6 (. 2).

(%)

		12	12 16	16
(=119)	13,1±0,6	58 48,6±4,2	40 3,8±4,0	22 7,6±3,2

41 (29,4%),

(.3).

3

(%)

		(= 119)
3		5 4,2±1,6
4-6		5 4,2±1,6
4-6		13 10,9±2,6
4-6		59 49,5±4,2
7-10		12 10,0±2,7
7-10		25 21,0±3,4

– 3 –5 (4,2%),

4-6 – 59 (49,6%)

4-6 – 5 (4,2%).

7-10 – 25 (21,0%).

4-6

13

(. 4)

(10,9%)

4

(%)

	-	-			:
	N91.4	N94.5	N92.0	N94.5	
(=119)	5 4,2±1,6	36 30,2±4,2	44 36,8±3,4	12 10,1±2,5	97 81,3±3,1

97 (81,3%)

– 79 (56,8%),

– 56

(40,3%),

30,2%,

36,8%.

(. 5).

(1.2009, 9)

(%)

		(= 119)
	N 70.0	79 (56,8±4,2%)
	28.9	56 (40,3 ±4,1%)
		37 (26,6 ±3,7%)
	N 80.0	35 (25,1 ±3,6%)
	N 97.1	35 (25,1±3,6%)
	N 83.1	49 (35,3 ±4,1%)
	D 25	30 (25,2±3,6%)

' . 6.

(%)

	(=119)
	97 (82,8+4,2%)
	61 (51,7+4,2%)
	40 (30,2±3,9%)
	49 (41,2±3,9%)
-	31 (25,8±3,7%)
	11 (9,3±2,4%)
	33 (28,1+3,8%)
	35 (28,9±3,3%)
	47 (39,4±3,5%)

97 (82,8%),

61 (51,7%)

49 (41,2%).

47 (39,4%),

- 9 -
 2 -
 -14 -
 - 4 -
 -
 -

7

	63 (77,7%) 14	53 (92,4%) 4	49
	28 (80,4%) 9	39 (94,8%) 2	37
	12 (80%) 4	16 (100%)	16
	16 4	12 (100%)	12
	- 2	2 (100%)	2
	- 2	2 (100%)	2

(
 .),

(,),

-
-
1.
 2.
 3.
 4.
http://www.rosoncweb.ru
 5.
 6.
(.) .
 7.
 8. (.) .
1999; 129-131.
 9.
 10. 2001; 24-28.
 11. 2001; 221.
 12.
 13. Bain C., Cooper K.G., Parkin D.E. Micro-wave endometrial ablation versus endometrial resection: a randomized controlled trial. *Obstet Gynecol* 2002; 99: 6: 983-987.
 14. Bakour S.H., Khan K.S., Gupta J.K. The risk of premalignant and malignant pathology in endometrial polyps. *Acta Obstet Gynecol Scand* 2002; 81: 2: 182-183.
 15. Boujida V.H., Philipsen T., Pelle J., Joergensen J.C. Five-year follow-up of endometrial ablation: endometrial coagulation versus endometrial resection. *Obstet Gynecol* 2002; 99: 6: 988-992.